News articles about TESARO (NASDAQ:TSRO) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. TESARO earned a news impact score of 0.18 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.1404780370245 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the news stories that may have impacted Accern Sentiment’s rankings:

TESARO (NASDAQ TSRO) opened at $84.39 on Monday. The company has a quick ratio of 4.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.34. TESARO has a 12-month low of $79.03 and a 12-month high of $192.94.

TESARO (NASDAQ:TSRO) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.69. The company had revenue of $142.77 million during the quarter, compared to analysts’ expectations of $130.57 million. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. TESARO’s quarterly revenue was up 740.3% on a year-over-year basis. During the same period last year, the business earned ($1.72) earnings per share. equities analysts predict that TESARO will post -8.17 earnings per share for the current fiscal year.

Several brokerages have weighed in on TSRO. Credit Suisse Group set a $190.00 price target on TESARO and gave the stock a “buy” rating in a report on Friday, August 18th. HC Wainwright reissued a “buy” rating and issued a $158.00 price target on shares of TESARO in a report on Monday, November 20th. Evercore ISI began coverage on TESARO in a report on Wednesday, August 16th. They issued an “in-line” rating and a $121.00 price target for the company. SunTrust Banks reissued a “buy” rating and issued a $160.00 price target on shares of TESARO in a report on Friday, November 10th. Finally, Argus set a $154.00 target price on TESARO and gave the stock a “buy” rating in a report on Tuesday, November 28th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $159.39.

In related news, SVP Martin H. Jr. Huber sold 829 shares of TESARO stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $85.24, for a total transaction of $70,663.96. Following the completion of the transaction, the senior vice president now directly owns 8,101 shares in the company, valued at $690,529.24. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director James O. Armitage sold 10,000 shares of TESARO stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $117.13, for a total value of $1,171,300.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at $1,171,300. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,421 shares of company stock valued at $1,312,175. 40.50% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: “TESARO (TSRO) Earning Somewhat Favorable News Coverage, Report Finds” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Insider Buying and Selling by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Stock Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related stocks with our FREE daily email newsletter.